Innocoll AG Company Profile (NASDAQ:INNL)

Analyst Ratings

Consensus Ratings for Innocoll AG (NASDAQ:INNL) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.50 (210.15% upside)

Analysts' Ratings History for Innocoll AG (NASDAQ:INNL)
Show:
DateFirmActionRatingPrice TargetActions
6/30/2016FBR & CoInitiated CoverageOutperform$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016Janney Montgomery ScottInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2014JMP SecuritiesInitiated CoverageMarket Outperform$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2014Stifel NicolausInitiated CoverageBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2014Piper Jaffray Cos.Initiated CoverageOverweight$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Innocoll AG (NASDAQ:INNL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/31/2016        
5/31/2016Q116($0.74)($0.90)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2016Q415($0.53)($0.72)$2.23 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q315($0.41)($0.54)$2.43 million$1.99 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2015Q215($0.24)($0.50)$2.06 million$637.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.28)($0.14)$1.99 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2015Q4($0.55)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014($0.58)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Innocoll AG (NASDAQ:INNL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Innocoll AG (NASDAQ:INNL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Innocoll AG (NASDAQ:INNL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Innocoll AG (NASDAQ:INNL)
DateHeadline
07/12/16 07:35 AMInnocoll (INNL) Catches Eye: Stock Jumps 5.4% in Session -
07/06/16 08:21 AMInnocoll Holdings plc to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference - [at noodls] - ATHLONE, Ireland, July 06, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL) a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas ...
06/30/16 04:53 PMFBR Capital covered (NASDAQ:INNL) Innocoll, hiking its price target to $18 today
06/30/16 11:11 AMEdited Transcript of INNL earnings conference call or presentation 31-May-16 8:30pm GMT -
06/30/16 05:18 AMCoverage initiated on Innocoll by FBR Capital -
06/27/16 11:48 AMInnocoll Holdings PLC (INNL) Could Pick Up Two US Approvals Before 2018 -
06/23/16 04:58 PMInnocoll completes enrollment in two late-stage studies of Cogenzia in diabetic foot infections, top-line data expected late Q3
06/23/16 08:09 AMInnocoll Holdings plc Announces the Completion of Enrollment in Two Pivotal Phase 3 Clinical Trials of COGENZIA for the Treatment of Diabetic Foot Infections - [at noodls] - ATHLONE, Ireland, June 23, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet ...
06/22/16 03:59 PMInnocoll Holdings plc Announces Closing of Public Offering - [at noodls] - ATHLONE, Ireland, June 22, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant ...
06/17/16 07:24 AMInnocoll AG (INNL) Prices 5.73M Ordinary Stock Offering at $7/Share
06/17/16 02:19 AM3:19 am Innocoll prices offering of 5,725,000 ordinary shares at $7.00 per share -
06/16/16 09:49 PMInnocoll Holdings plc Announces Pricing of Public Offering of Ordinary Shares - [at noodls] - ATHLONE, Ireland, June 16, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas ...
06/16/16 08:20 AMInnocoll Holdings plc to Present at the JMP Securities Life Sciences Conference - [GlobeNewswire] - ATHLONE, Ireland, June 16, 2016-- Innocoll Holdings plc a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, ...
06/13/16 03:49 PMInnocoll Holdings plc Announces Proposed Public Offering of Ordinary Shares - [at noodls] - ATHLONE, Ireland, June 13, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL) a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas ...
06/01/16 04:59 PMHandbag maker Michael Kors' sales rise 10.9 pct - Revenue, meanwhile, rose to $1.2 billion from $1.08 billion a year ago. Innocoll Holdings plc (NASDAQ:INNL) reported a net loss attributable to its ordinary shares of $23.1 million, or $0.97 per share of Innocoll Holdings plc, for the first quarter of 2016 ...
06/01/16 04:59 PMInnocoll's (INNL) CEO Tony Zook on Q1 2016 Results - Earnings Call Transcript - Greetings, and welcome to the Innocoll Holdings plc First Quarter 2016 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions ...
05/31/16 03:33 PMInnocoll reports 1Q loss -
05/26/16 09:21 AMInnocoll Stock Gains on Favorable Phase III Data on Xaracoll -
05/25/16 06:30 AMInnocoll Announces XARACOLL® (bupivacaine-collagen bioresorbable implant) Meets Primary Endpoint in Both Pivotal Phase 3 Trials in Postoperative Pain Relief - [GlobeNewswire] - First long-acting, opioid-sparing, local analgesic to meet primary endpoints of Phase 3 clinical trials in hernia repair Data supports on-schedule NDA filing this year Results validate the Innocoll technology ...
05/24/16 03:15 PMInnocoll to Host Live Webcast on Top-Line Results from Two Pivotal Phase 3 Trials of XARACOLL® (bupivacaine-collagen bioresorbable implant) in Postoperative Pain Relief - [GlobeNewswire] - ATHLONE, Ireland, May 24, 2016-- Innocoll, a global, commercial-stage, specialty pharmaceutical company, today announced that the Company will host a live webcast and conference call to review top-line ...
05/18/16 03:10 PMInnocoll to Report First Quarter 2016 Financial Results and Host Webcast and Conference Call on May 31, 2016 - [GlobeNewswire] - ATHLONE, Ireland, May 18, 2016-- Innocoll Holdings plc, a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices ...
04/20/16 03:44 PMInnocoll Holdings plc Appoints Lesley Russell, MBChB, MRCP, as Chief Medical Officer - [GlobeNewswire] - ATHLONE, Ireland, April 20, 2016-- Innocoll Holdings plc, a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, today announced ...
03/17/16 07:00 AMInnocoll Holdings plc Announces Fourth Quarter and Full-Year 2015 Financial and Operating Results and Provides Corporate Update - [GlobeNewswire] - ATHLONE, Ireland, March 17, 2016-- Innocoll Holdings plc, a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need announced financial ...
03/17/16 06:07 AMQ4 2015 Innocoll AG Earnings Release - Before Market Open -
03/11/16 03:30 PMInnocoll to Report Fourth Quarter 2015 Financial Results and Host Webcast and Conference Call on March 17, 2016 - [GlobeNewswire] - ATHLONE, Ireland, March 11, 2016-- Innocoll AG, a global, commercial stage, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, today ...
02/11/16 01:05 PMInnocoll AG (INNL) - Medical Equipment - Deals and Alliances Profile - New Market Report - (live-PR.com) - Innocoll AG (Innocoll) is a specialty pharmaceutical company which carries out the development and manufacturing of surgical implants and topically applied healthcare products in the areas of unmet clinical needs. The company's product ...
12/23/15 08:46 AMInnocoll AG Earnings Analysis: Q3, 2015 By the Numbers -
12/17/15 07:56 AMInnocoll AG Appoints Charles Katzer as Head of Manufacturing and Technical Operations - [at noodls] - ATHLONE, , (GLOBE NEWSWIRE) -- (NASDAQ:INNL) announced that has been appointed head of Manufacturing and Technical Operations effective immediately. The addition of this role to the senior management team ...
12/09/15 03:49 PMInnocoll AG Announces Plan to Move Corporate Domicile to Ireland - [at noodls] - ATHLONE, Ireland, Dec. 09, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL) today announced that its supervisory board has unanimously approved a plan to move the company's legal domicile from Germany ...
12/08/15 12:07 PMINNOCOLL AG Financials -
11/29/15 11:25 AMHedge Funds Are Buying OraSure Technologies, Inc. (OSUR) -
11/24/15 04:25 PMIs CIBER, Inc. (CBR) A Good Stock To Buy? -
11/11/15 07:46 AMInnocoll AG Announces Third Quarter 2015 Financial and Operating Results and Corporate Update - [at noodls] - ATHLONE, Ireland, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products ...
11/11/15 06:07 AMQ3 2015 Innocoll AG Earnings Release - Before Market Open -
11/04/15 04:08 PMInnocoll to Report Third Quarter 2015 Financial Results and Host Webcast and Conference Call on November 11, 2015 - [at noodls] - ATHLONE, Ireland, Nov. 04, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) (the 'Company'), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical ...
09/17/15 10:23 AMInnocoll AG Earnings Q2, 2015 -
09/16/15 07:09 AMInnocoll AG Announces First Patient Dosed in the XaraColl MATRIX-2 Phase 3 Study for the Treatment of Postoperative Pain - [at noodls] - ATHLONE, Ireland, Sept. 16, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical ...
09/14/15 07:15 AMInnocoll AG Announces Departure of Chief Medical Officer - [at noodls] - ATHLONE, Ireland, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL) announced that James P. Tursi, M.D., will depart Innocoll to pursue another opportunity. Dr. Tursi will remain with Innocoll ...
09/02/15 07:24 AMInnocoll AG Announces First Patient Dosed in the XaraColl MATRIX-1 Phase 3 Study for the Treatment of Postoperative Pain - [at noodls] - ATHLONE, Ireland, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical ...
08/14/15 07:51 AMInnocoll AG Announces Second Quarter 2015 Financial and Operating Results and Updates Late-Stage Product Portfolio Progress - [at noodls] - ATHLONE, Ireland, Aug. 14, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical ...

Social

About Innocoll AG

Innocoll Holdings plc is a commercial-stage specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need. The Company utilizes its collagen-based technology platform to develop biodegradable and fully bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. The Company's products combine proven therapeutics, including small molecules and biologics, with highly customized drug release profiles, localized drug delivery and superior handling properties. The Company uses code names to refer to its products in development. The Company's products include INL-001 (XaraColl), INL-002 (Cogenzia) and INL-003 (CollaGUARD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INNL
  • CUSIP:
Key Metrics:
  • Previous Close: $5.32
  • 50 Day Moving Average: $6.61
  • 200 Day Moving Average: $7.94
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $125.88M
  • Beta: 0.32
  • Current Year EPS Consensus Estimate: $-2.58 EPS
  • Next Year EPS Consensus Estimate: $-1.55 EPS
Additional Links:
Innocoll AG (NASDAQ:INNL) Chart for Wednesday, July, 27, 2016